• Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

    Thursday December 3rd 2020

  • reMYND commences first-in-human trial of ReS19-T Alzheimer’s program

    Thursday December 3rd 2020

  • Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial

    Tuesday December 1st 2020

  • Biocartis announces publication of large multi-center comparison study with Idylla™ MSI Assay showing very low failure rates and excellent concordance with reference methods

    Tuesday November 17th 2020

  • First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial

    Tuesday November 10th 2020

  • Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study

    Tuesday October 20th 2020

  • Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients

    Friday October 16th 2020

  • Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion

    Wednesday October 14th 2020

  • Your news here?

  • Phase 2B/3 Trial shows efficacy of Filgotinib for the induction and maintenance of remission in moderately and severely active Ulcerative Colitis

    Tuesday October 13th 2020

  • argenx presents additional Efgartigimod data from Global Phase 3 ADAPT Trial

    Monday October 5th 2020

  • Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial

    Wednesday September 30th 2020

Strategic Partners